Trevi Therapeutics (TRVI) said Monday it has priced an underwritten offering of 12.5 million common shares at $4.00 each for gross proceeds of $50 million.
The offering is expected to close Tuesday, pending the fulfillment of customary closing conditions, and includes participation from investors including Adage Capital Partners, Frazier Life Sciences, Logos Capital, MPM BioImpact, Rubric Capital and Vivo Capital, Trevi said.
Shares of the clinical stage biopharmaceutical company were up 3.8% in recent Monday trading.
Price: 4.33, Change: +0.16, Percent Change: +3.84
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.